Nosha Farhadfar
A5020415674- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Renal Transplantation Outcomes and Treatments
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Cancer survivorship and care
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Mesenchymal stem cell research
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Gut microbiota and health
- T-cell and B-cell Immunology
- Corneal Surgery and Treatments
- Polyomavirus and related diseases
- Multiple Myeloma Research and Treatments
- Transplantation: Methods and Outcomes
- Blood transfusion and management
- Cancer Treatment and Pharmacology
- Organ Transplantation Techniques and Outcomes
- Palliative Care and End-of-Life Issues
Florida College
2019-2024
University of Florida
2017-2024
Methodist Hospital
2024
Sarah Cannon
2024
Houston Methodist
2024
Methodist Hospital
2024
Baptist Medical Center Jacksonville
2024
UF Health Shands Hospital
2018-2022
University of Florida Health
2018-2022
University of Florida Health Science Center
2018-2021
Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need novel therapeutics. ABA2 was phase II trial to rigorously assess safety, efficacy, and immunologic effects adding T-cell costimulation blockade with abatacept calcineurin inhibitor...
Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched donor, with significant disparity across ethnic groups. We hypothesized that HCT a mismatched (MMUD) post-transplant cyclophosphamide (PTCy), novel strategy successful in overcoming genetic related donors, would be feasible and...
Recognition of the earliest signs and symptoms chronic graft-versus-host disease (GVHD) that lead to severe manifestations remains a challenge. The standardization provided by National Institutes Health (NIH) 2005 2014 consensus projects has helped improve diagnostic accuracy severity scoring for clinical trials, but utilization these tools in routine practice is variable. Additionally, when patients meet NIH criteria, many already have significant morbidity possibly irreversible organ...
Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling (MSD) is still considered the optimal donor. Using Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) first complete remission (CR1). Data from 1205 adult CR1 AML (2008-2015) were analyzed. A total...
Abstract The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes HCT approaches by donor adults with ALL in remission. primary objective was to compare overall survival (OS) among HCTs PTCy and HLA-matched sibling (MSD), 8/8 unrelated (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing MSD HCT,...
Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic syndrome even if they older. However, whether older MSDs or younger human leukocyte antigen-matched unrelated (MUDs) associated with better outcomes remains unclear.To investigate allo-HCT using MUDs would be improved disease-free survival and less relapse compared MSDs.This retrospective cohort study assessed data reported to the Center International Blood Marrow...
Background Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease older adults. Methods The authors investigated outcomes AHCT MM who were aged ≥70 years. Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 United States within 12 months diagnosis during 2013 through 2017; total 2092 Nonrecurrence mortality (NRM), recurrence and/or...
Patients undergoing hematopoietic stem cell transplant (HSCT) are at risk for bloodstream infection (BSI) secondary to translocation of bacteria through the injured mucosa, termed mucosal barrier injury-laboratory confirmed (MBI-LCBI), in addition BSI indwelling catheters and other sites (BSI-other).To determine incidence, timing, factors, outcomes patients who develop MBI-LCBI first 100 days after HSCT.A case-cohort retrospective analysis was performed using data from Center International...
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from Center International Blood and Marrow Transplant Research on adult patients acute myeloid leukemia, lymphoblastic myelodysplastic syndrome, or chronic leukemia who...
Abstract Richter syndrome (RS) represents a transformation from chronic lymphocytic leukemia/small lymphoma (CLL/SLL) to aggressive lymphoma, most commonly diffuse large B-cell (DLBCL), which is associated with dismal prognosis. Patients DLBCL-RS have poor outcomes DLBCL-directed therapy; thus, consolidation hematopoietic cell transplantation (HCT) has been used, durable remissions observed. Studies reporting HCT in patients small, not evaluated the prognostic impact of cytogenetic risk...
The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions GVHD and improved outcomes allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year first multicenter prospective clinical trial PTCy setting mismatched unrelated donor (MMUD) bone marrow HCT. study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity (RIC;...
<h3>Importance</h3> Reduced-intensity conditioning and nonmyeloablative (RIC-NMAC) regimens are frequently used in allogeneic hematopoietic cell transplant (HCT) for non-Hodgkin lymphoma. However, the optimal RIC-NMAC regimen HCT lymphoma is not known. <h3>Objective</h3> To investigate whether at a higher end of intensity spectrum associated with increased nonrelapse mortality lower overall survival compared patients undergoing HCT. <h3>Design, Setting, Participants</h3> This cohort study...
Abstract There is marked paucity of data regarding late effects in adolescents and young adults (AYAs) who undergo myeloablative conditioning (MAC) allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). We evaluated survival 826 1-year disease-free survivors MAC HCT AYA AML, with an additional focus on comparing based upon type (total body irradiation [TBI] vs high-dose chemotherapy only). The estimated 10-year cumulative incidence subsequent neoplasms was 4%...
Abstract Allogeneic hematopoietic cell transplantation (allo‐HCT) is a potentially curative treatment for acute myeloid leukemia (AML) and lymphoblastic (ALL). While many factors influence the outcomes of allo‐HCT, independent impact donor–recipient ABO mismatching remains unclear. Using Center International Blood Marrow Transplant Research (CIBMTR) database, we identified patients aged ≥18 years with AML or ALL who underwent allo‐HCT between 2008 2018. Our objectives were to analyze based...
Abstract Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns cardiovascular toxicity from its use. With this study, we aim to further study hazards underlying risk factors adverse events associated with carfilzomib. This conducted using Surveillance, Epidemiology, End Results (SEER)‐Medicare data set 2001 2015. Data were analyzed ratio between carfilzomib users nonusers. We identified 7330 patients whom 815 users. had a statistically...
The COVID-19 pandemic has resulted in the increased use of cryopreserved grafts for allogeneic hematopoietic cell transplantation (HCT). However, information about effect cryopreservation on outcomes patients receiving donor is limited. We evaluated HCT recipients who received either fresh or bone marrow (BM) peripheral blood stem (PBSC) reported to Center International Blood and Marrow Transplant Research. A total 7397 were included analysis. Recipients graft divided into 3 cohorts based...
Chronic graft-versus-host disease (GVHD) commonly occurs after allogeneic hematopoietic cell transplantation (HCT) despite standard prophylactic immune suppression. Intensified universal prophylaxis approaches are effective but risk possible overtreatment and may interfere with the graft-versus-malignancy response. Here we summarize conceptual practical considerations regarding preemptive therapy of chronic GVHD, namely interventions applied HCT based on evidence that developing GVHD is...
Somatic mutations are recognized as an important prognostic factor in chronic myelomonocytic leukemia (CMML). However, limited data available regarding their impact on outcomes after allogeneic hematopoietic cell transplantation (HCT). In this registry analysis conducted collaboration with the Center for International Blood and Marrow Transplantation Registry database/sample repository, we identified 313 adult patients CMML (median age: 64 years, range, 28- 77) who underwent HCT during...